{"id":"W4403455062","doi":"10.1016/j.esmoop.2024.103938","title":"Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Kelowna General Hospital","funders":"National Cancer Institute; ECOG-ACRIN Cancer Research Group; National Institutes of Health; Meso Scale Diagnostics; Gilead Sciences; American College of Radiology Imaging Network; Roche; Canadian Cancer Society; GlaxoSmithKline; AstraZeneca; Novartis; Pfizer","keywords":"Lapatinib; Trastuzumab; Medicine; Breast cancer; Oncology; Internal medicine; Adjuvant; Cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00748097,0.001205027,0.001755533,0.0003437975,0.0002678222,0.001195344,0.0008056228,0.001042476,0.003250104],"category_scores_gemma":[0.003391993,0.000354092,0.002946336,0.0003455326,0.0005527663,0.0009807873,0.0006129552,0.001989034,0.0005979773],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007330197,"about_ca_system_score_gemma":0.001194671,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004875345,"about_ca_topic_score_gemma":0.001415401,"domain_scores_codex":[0.9975617,0.001710164,0.00009452291,0.0002315523,0.0001857827,0.0002163049],"domain_scores_gemma":[0.9981697,0.0004522826,0.0005293647,0.000162103,0.0002167881,0.0004697194],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9417948,0.002249431,0.009075922,0.0009020893,0.005826252,0.0001256106,0.00008524389,0.002990525,0.004992655,0.0005153738,0.007223621,0.02421848],"study_design_scores_gemma":[0.7601652,0.1713858,0.03998489,0.000201525,0.008989507,0.000313169,0.00007155931,0.003279752,0.002355823,0.0009561955,0.01221117,0.00008541175],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9531259,0.01379975,0.003345478,0.002758664,0.0006331605,0.004959562,0.0109195,0.0002455027,0.01021243],"genre_scores_gemma":[0.9619801,0.002320245,0.003330397,0.002265318,0.0006459305,0.00409206,0.02036446,0.00008764985,0.004913795],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00748097,"threshold_uncertainty_score":0.0395636,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07178304164162665,"score_gpt":0.3880955706819111,"score_spread":0.3163125290402845,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}